|
1）Nakatogawa H, Suzuki K, Kamada Y, et al. Dynamics and diversity in autophagy mechanisms: lessons from yeast. Nat Rev Mol Cell Biol. 2009; 10(7): 458-67
|
|
|
|
2）Tanida I. Autophagosome formation and molecular mechanism of autophagy. Antioxid Redox Signal. 2011; 14(11): 2201-14
|
|
|
|
|
|
3）Asanuma K, Tanida I, Shirato I, et al. MAP-LC3, a promising autophagosomal marker, is processed during the differentiation and recovery of podocytes from PAN nephrosis. FASEB J. 2003; 17(9): 1165-7
|
|
|
|
|
|
4）Mizushima N, Yamamoto A, Matsui M, et al. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell. 2004; 15(3): 1101-11
|
|
|
|
|
|
5）Hartleben B, Godel M, Meyer-Schwesinger C, et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Invest. 2010; 120(4): 1084-96
|
|
|
|
|
|
6）Yadav A, Vallabu S, Arora S, et al. ANG II promotes autophagy in podocytes. Am J Physiol Cell Physiol. 2010; 299(2): C488-96
|
|
|
|
|
|
7）Ichihara A, Kaneshiro Y, Takemitsu T, et al. The (pro)renin receptor and the kidney. Semin Nephrol. 2007; 27(5): 524-8
|
|
|
|
|
|
8）Sakoda M, Ichihara A, Kurauchi-Mito A, et al. Aliskiren inhibits intracellular angiotensin II levels without affecting (pro)renin receptor signals in human podocytes. Am J Hypertens. 2010; 23(5): 575-80
|
|
|
|
|
|
9）Oshima Y, Kinouchi K, Ichihara A, et al. Prorenin receptor is essential for normal podocyte structure and function. J Am Soc Nephrol. 2011; 22(12): 2203-12
|
|
|
|
|
|
10）Riediger F, Quack I, Qadri F, et al. Prorenin receptor is essential for podocyte autophagy and survival. J Am Soc Nephrol. 2011; 22(12): 2193-202
|
|
|
|
|
|
11）Sou YS, Tanida I, Komatsu M, et al. Phosphatidylserine in addition to phosphatidylethanolamine is an in vitro target of the mammalian Atg8 modifiers, LC3, GABARAP, and GATE-16. J Biol Chem. 2006; 281(6): 3017-24
|
|
|
|
|
|
12）Kabeya Y, Mizushima N, Yamamoto A, et al. LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J Cell Sci. 2004; 117(Pt 13): 2805-12
|
|
|
|
|
|
13）Weidberg H, Shvets E, Shpilka T, et al. LC3 and GATE-16/GABARAP subfamilies are both essential yet act differently in autophagosome biogenesis. EMBO J. 2010; 29(11): 1792-802
|
|
|
|
|
|
14）Takagi-Akiba M, Asanuma K, Tanida I, et al. Doxorubicin-induced glomerulosclerosis with proteinuria in GFP-GABARAP transgenic mice. Am J Physiol Renal Physiol. 2011; 302: F380-9
|
|
|
|
|
|
15）Weide T, Huber TB. Implications of autophagy for glomerular aging and disease. Cell Tissue Res. 2011; 343(3): 467-73
|
|
|
|
|
|
16）Godel M, Hartleben B, Herbach N, et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest. 2011; 121(6): 2197-209
|
|
|
|
|
|
17）Inoki K, Mori H, Wang J, et al. mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest. 2011; 121(6): 2181-96
|
|
|
|
|
|
18）Cina DP, Onay T, Paltoo A, et al. Inhibition of MTOR disrupts autophagic flux in podocytes. J Am Soc Nephrol. 2012; 23(3): 412-20
|
|
|
|
|
|
19）Ito N, Nishibori Y, Ito Y, et al. mTORC1 activation triggers the unfolded protein response in podocytes and leads to nephrotic syndrome. Lab Invest. 2011; 91(11): 1584-95
|
|
|
|
|